Antibodies to endothelial cells in borderline hypertension

Circulation

Volumn 98, Issue 11, 1998, Pages 1092-1098

  Frostegård, Johan ^a   Wu, Ruihua ^a   Gillis Haegerstrand, Caroline ^a   Lemne, Carola ^a   De Faire, Ulf ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antibodies; Atherosclerosis; Endothelium; Glycoproteins; Hypertension

Indexed keywords

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HYPERTENSION; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0032530255     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.11.1092     Document Type: Article

References (48)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. De Meyer GR, Herman AG. Vascular endothelial dysfunction. Prog Cardiovasc Dis. 1997;39:325-342.
3. Nava E, Luscher TF. Endothelium-derived vasoactive factors in hypertension: nitric oxide and endothelin. J Hypertens. 1995;13(suppl):39-48.
4. Frostegård J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low-density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci U S A. 1990;87:904-908.
5. Frostegård J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Induction of T cell activation by oxidized low density lipoprotein. Arterioscler Thromb. 1992;12:461-467.
6. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995;92:3893-3897.
7. Frostegård J, Huang YH, Rönnelid J, Schäfer-Elinder L. PAF and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol. 1997;17:963-968.
8. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyssonen K, Palinski W, Witztum JL. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 1992;339: 883-887.
9. Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vase Biol. 1995;15: 441-445.
10. Dzielak DJ. The immune system and hypertension. Hypertension. 1992; 19:136-144.
11. Fu ML. Do immune system changes have a role in hypertension? J Hypertens. 1995;13:1259-1265.
12. Frostegård J, Lemne C, Andersson B, Kiessling R, de Faire U. Association of serum antibodies to heat shock protein 65 with borderline hypertension. Hypertension. 1997;29:40-44.
13. Quadros NP, Roberts-Thomson PJ, Gallus AS. IgG, and IgM anti-endothelial cell antibodies in patients with collagen vascular disorders. Rheumatol Int. 1990;10:113-119.
14. Del Papa N, Guidali L, Sironi M, Shoenfeld Y, Mantovani A, Tincani A, Balestriera G, Radice A, Sinico RA, Meroni PL. Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. Arthritis Rheum. 1996;39:758-766.
15. Eichhorn J, Sima D, Thiele B, Lindschau C, Turowski A, Schmidt H, Schneider W, Haller H, Luft FC. Anti-endothelial cell antibodies in Takayasu arteritis. Circulation. 1996;94:2396-2401.
16. Salojin KV, Le Tongqueze M, Nassovov EL, Blouch MT, Baranov AA, Saraux A, Guillevin L, Fiessinger JN, Piette JC, Youinou P. Anti-endothelial cell antibodies in patients with various forms of vasculitis. Clin Exp Rheumatol. 1996;14:163-169.
17. Olee T, Pierangeli SS, Handley HH, Le DT, Wei X, Lai CJ, En J, Novotny W, Harris EN, Woods VL, Chen PP. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc Natl Acad Sci U S A. 1996;93:8606-8611.
18. Damianovich M, Gilburd B, George J, Del Papa N, Afek A, Goldberg I, Kopolovic Y, Roth D, Barkai G, Meroni PL, Shoenfeld Y. Pathogenic role of anti-endothelial cell antibodies in vasculitis: an idiotypic experimental model. J Immunol. 1996;156:4946-4951.
19. Hill MB, Phipps JL, Milford-Ward A, Greaves M, Hughes P. Further characterization of anti-endothelial cell antibodies in lupus erythematosus by controlled immunoblotting. Br J Rheumatol. 1996;35:1231-1238.
20. Hamsten A, Bjorkholm M, Norberg R, de Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet. 1986;1:113-116.
21. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
22. Lemne C, Jogestrand T, de Faire U. Carotid intima-media thickness and plaque in borderline hypertension. Stroke. 1995;26:34-39.
23. Haegerstrand A, Gillis C, Bengtsson L. Serial cultivation of adult human endothelium from the great saphenous vein. J Vasc Surg. 1992;16: 280-285.
24. Amiral J, Larrivaz I, Cluzeau D, Adam M. Standardization of immunoassays for antiphospholipid antibodies with beta 2GP1 and role of other phospholipid cofactors. Haemostasis. 1994;24:191-203.
25. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol. 1986;68:215-222.
26. Carlson K. Lipoprotein fractionation. J Clin Pathol. 1973;5(suppl 26): 32-37.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
28. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137:959-965.
29. Pavoa G, Roovete A, Hall K. Cross reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol. 1991;124:620-629.
30. Lemne C, Lundeberg T, Theodorsson E, de Faire U. Increased basal concentrations of plasma endothelin in borderline hypertension. J Hypertens. 1994;12:1069-1074.
31. Lemne C, Lindvall K, Georgiades A, Fredriksson M, de Faire U. Structural cardiac changes in relation to 24 hour ambulatory blood pressure levels in borderline hypertension. J Intern Med. 1995;238: 49-57.
32. Lemne C, Jogestrand T, de Faire U. Non-invasive assessment of vessel-wall change in hypertensives and normotensive controls. Clin Physiol. 1992;12:497-502.
33. Lemne C, Hamsten A, Karpe F, Nilsson-Ehle P, de Faire U. Dyslipoproteinemic changes in borderline hypertension. Hypertension. 1994;24: 605-610.
34. Nityanand S, Bergmark C, de Faire U, Swedenborg J, Holm G, Lefvert AK. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med. 1995;238:437-443.
35. Ihrcke NS, Platt JL. Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. J Cell Physiol. 1996;168:625-637.
36. Luscher TF, Wenzel RR. Endothelin and endothelin antagonists: pharmacology and clinical implications. Agents Actions. 1995;45:237-253.
37. Filep JG, Bodolay E, Sipka S, Gyimesi E, Csipö I, Szegedi G. Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Circulation. 1995;92:2969-2974.
38. Yoshio T, Masuyama J, Mimori A, Takeda A, Minota S, Kano S. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis. 1995;54: 361-365.
39. Cook PJ, Lip GY. Infectious agents and atherosclerotic vascular disease. Q J Med. 1996;89:727-735.
40. Delneste Y, Lassalle P, Jeannin P, Mannessier L, Dessaint JP, Joseph M, Tonnel AB. Production of anti-endothelial cell antibodies by cocullure of EBV infected human B cells with endothelial cells. Cell Immunol. 1993; 150:15-26.
41. Gladman DD. Prognosis of systemic lupus erythematosus and factors that affect it. Curr Opin Rheumatol. 1990;2:694-702.
42. Hörkkö S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch W, Palinski W, Witztum J. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest. 1996;98:815-825.
43. Del Papa N, Guidali L, Spatola L, Bonara B, Borghi MO, Tincani A, Balestriera G, Meroni PL. Relationship between anti-phospholipid and anti-endothelial cell antibodies, III: beta 2 glycoprotein 1 mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol. 1995;13:179-185.
44. Najmey SS, Keil LB, Adib DY, DeBari VA. The association of antibodies to beta 2 glycoprotein 1 with the antiphospholipid syndrome: a meta-analysis. Ann Clin Lab Sci. 1997;27:41-46.
45. Hollander W, Prusty S, Kemper T, Rosene DL, Moss MB. The effects of hypertension on cerebral atherosclerosis in the cynomolgus monkey. Stroke. 1993;24:1218-1226.
46. Sawchuk AP, Unthank JL, Davis TE, Dalsing MC. A prospective, in vivo study of the relationship between blood flow hemodynamics and atherosclerosis in a hyperlipidemic swine model. J Vasc Surg. 1994; 19:58-63.
47. Solberg LA, Strong JP. Risk factors and atherosclerotic lesions: a review of autopsy studies. Arteriosclerosis. 1983;3:187-198.
48. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Hishi S, Koike T. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol. 1997;107:569-573.